Overview

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

Status:
Completed

Trial end date:
2021-03-29

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease.

Phase:

Phase 3

Details

Lead Sponsor:

Ferring Pharmaceuticals

Collaborators:

Duke Clinical Research Institute
Memorial Sloan Kettering Cancer Center

Treatments:

Leuprolide